quinoxalines has been researched along with 1-(3-chlorophenyl)biguanide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garraway, SM; Hochman, S | 1 |
| Gupta, D; Radhakrishnan, M; Thangaraj, D | 1 |
2 other study(ies) available for quinoxalines and 1-(3-chlorophenyl)biguanide
| Article | Year |
|---|---|
Serotonin increases the incidence of primary afferent-evoked long-term depression in rat deep dorsal horn neurons.
Topics: Afferent Pathways; Amphetamines; Animals; Animals, Newborn; Biguanides; Boron Compounds; Excitatory Postsynaptic Potentials; Long-Term Potentiation; Methacrylates; Methylmethacrylates; Nerve Tissue Proteins; Neuronal Plasticity; Patch-Clamp Techniques; Posterior Horn Cells; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Receptor Agonists; Single-Blind Method; Synaptic Transmission | 2001 |
A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.
Topics: Animals; Antidepressive Agents; Biguanides; Brain; Depressive Disorder; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoxetine; Male; Mice; Quinoxalines; Random Allocation; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2016 |